Disclaimer: This site aggregates publicly available data from official government sources (FDA, ClinicalTrials.gov, PubMed, SEC EDGAR, NMPA) for general reference only. It does NOT constitute medical advice, diagnosis, treatment recommendations, or investment advice.

Clinical Trial

Pediatric Prospective Personalized Immune and Target Identification Trial

NCT: NCT04859543 · COMPLETED

NCT IDNCT04859543
StatusCOMPLETED
Start Date2021-02-02
Completion2024-12-10

Brief Summary

PPROSPERITIT is a prospective clinical study assessing the use of comprehensive molecular profiling to define the best matching targeted and immune treatment for relapsed, refractory or very high risk pediatric CNS tumors.

Frequently Asked Questions

What is Pediatric Prospective Personalized Immune and Target Identification Trial?

Pediatric Prospective Personalized Immune and Target Identification Trial is a clinical trial registered under NCT04859543. Current status: COMPLETED.

What is the status of NCT04859543?

The current status of NCT04859543 (Pediatric Prospective Personalized Immune and Target Identification Trial) is: COMPLETED.

When did Pediatric Prospective Personalized Immune and Target Identification Trial start?

Pediatric Prospective Personalized Immune and Target Identification Trial started on 2021-02-02.

Official Source

View on ClinicalTrials.gov →

Data sourced from ClinicalTrials.gov API. For the most current status, refer to the official record.

↑